 |
66 Diseases |  |
1 Trial |
|
1 Trial |  |
15 News |  |
- | Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
Journal: High Prevalence of Iron Deficiency Despite Standardized High-Dose Iron Supplementation During Recombinant Erythropoietin Therapy in Extremely Low Gestational Age Newborns. (Pubmed Central) - Nov 26, 2020
In extremely low gestational age newborns, r-HuEPO therapy promoted erythropoiesis. Despite a biomarker-based standardized high-dose iron supplementation, the majority of infants had evidence of iron deficiency to a degree that is associated with reduced brain function.
- || Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
#OncoAlert @OncoAlert AE toxicity repoting drug label updates common within first decade of drug approval 👆 (Twitter) - Dec 3, 2019
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 9, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Despite a biomarker-based standardized high-dose iron supplementation, the majority of infants had evidence of iron deficiency to a degree that is associated with reduced brain function. Trial primary completion date: Jan 2010 --> May 2004
- | Epogen (epoetin alfa) / Amgen
Trial completion: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 8, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jan 2010 --> May 2004 Active, not recruiting --> Completed
- |||||||||| Epoch (epoetin beta biosimilar) / Roche
New P3 trial: A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy (clinicaltrials.gov) - May 10, 2016
P3, N=61, Completed, Sponsor: Hoffmann-La Roche
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 28, 2015
P3, N=118, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Jan 2, 2015
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Trial primary completion date: Nov 2003 --> Jan 2010
- Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
Trial termination: Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment (clinicaltrials.gov) - Jan 26, 2014
P3, N=8, Terminated, Sponsor: Chulalongkorn University
Trial primary completion date: Nov 2003 --> Jan 2010 Recruiting --> Terminated; We observed >90 % efficacy in cyclophosphamide and Prednisolone group for treatment of anti-i-HuEpo associated PRCA
- Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
Enrollment change: Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment (clinicaltrials.gov) - Jan 26, 2014
P3, N=8, Terminated, Sponsor: Chulalongkorn University
Recruiting --> Terminated; We observed >90 % efficacy in cyclophosphamide and Prednisolone group for treatment of anti-i-HuEpo associated PRCA N=16 --> 8
- ||| Repotin (recombinant human erythropoietin biosimilar) / Genius Biotherapeutics
Enrollment change: A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment (clinicaltrials.gov) - Apr 28, 2013
P4, N=52, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=16 --> 8 N=150 --> 52